Drug Profile
Tazarotene - Ortho Dermatologics
Alternative Names: ARAZLO; IDP-123Latest Information Update: 26 Dec 2022
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class Antiacnes; Antipsoriatics; Esters; Keratolytics; Nicotinic acids; Pyrans; Pyridines; Retinoids
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acne vulgaris
Most Recent Events
- 22 Dec 2022 Launched for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in Canada (Topical)
- 05 Aug 2021 9331373: Approval info added, KDM updated, advanced dev line, intro updated
- 04 Aug 2021 Preregistration for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in Canada (Topical), prior to August 2021